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ABSTRACT
Purpose The increasing prevalence and treatment costs of kid-
ney diseases call for innovative therapeutic strategies that prevent
disease progression at an early stage. We studied a novel method
of subcapsular injection of monodisperse microspheres, to use as
a local delivery system of drugs to the kidney.
Methods We generated placebo- and rapamycin monodisperse
microspheres to investigate subcapsular delivery of drugs. Using a rat
model of acute kidney injury, subcapsular injection of placebo and
rapamycin monodisperse microspheres (monospheres) was com-
pared to subcutaneous injection, mimicking systemic administration.
Results We did not find any adverse effects related to the deliv-
ery method. Irrespective of the injection site, a similar low dose of
rapamycin was present in the circulation. However, only local
intrarenal delivery of rapamycin from monospheres led to de-
creased macrophage infiltration and a significantly lower amount
of myofibroblasts in the kidney, where systemic administration did
not. Local delivery of rapamycin did cause a transient increase in
the deposition of collagen I, but not of collagen III.
Conclusions We conclude that therapeutic effects can be
increased when rapamycin is delivered subcapsularly by
monospheres, which, combined with low systemic concentra-
tions, may lead to an effective intrarenal delivery method.
KEY WORDS ischemia reperfusion . kidney . local drug
delivery . microspheres . rapamycin
ABBREVIATIONS
AKI Acute kidney injury
GFR Glomerular filtration rate







RCH Rapamycin subcapsular high dose
RCL Rapamycin subcapsular low dose
RSc Rapamycin subcutaneous high dose
α-SMA α-smooth muscle actin
INTRODUCTION
Acute kidney injury (AKI), caused for example by kidney
transplantation or surgery-related ischemia/reperfusion, trig-
gers inflammation irrespective of damage type. Inadequate
treatment of the inflammatory phase after AKI leads to an
excessive wound healing response, resulting in the deposition
of large amounts of collagen (1,2). This fibrotic response oc-
curring after insufficient recovery from AKI will lead to end
stage renal disease and finally to kidney failure. In this final
stage patients require renal replacement therapy, such as di-
alysis or kidney transplantation, which is costly and in the long
term insufficient. For that reason, a solution should be sought
in an early intervention during the inflammatory phase, in
order to prevent fibrosis. To investigate whether this is possi-
ble we used an AKI rat model to see whether we can control
the hostile microenvironment of the kidney. Although rats and
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humans differ in their response toward AKI we hypothesize
that controlling the microenvironment after damage can lead
to a better outcome.
Current treatments after AKI are based on slowing
down or controlling the conditions that eventually may
lead to chronic kidney disease, and include medication
to decrease blood pressure and / or cholesterol, to re-
duce swelling or to treat anemia (3). After transplanta-
tion, oral medication needs to be taken in order to prevent
rejection or inflammation (4). These treatments are not fo-
cused on treating the damage caused in the kidney by ischemic
stress or other factors. This means that, even when the cause of
kidney disease is being treated, the process of kidney disease
may be ongoing.
Site-specific release of therapeutic compounds by
means of an injectable drug delivery vehicle allows for
optimal therapeutic effect at the site of interest, while
minimizing systemic loss and undesirable side effects of
the drug in the rest of the body, as reviewed by Kumar
et al. (5). Biodegradable microspheres (MSP) are inter-
esting vehicles for this type of drug delivery due to their
capacity to release drugs controllably with respect to
duration and dosage (6). Previously we have examined
the use of differently sized MSP, and hypothesized that
monodisperse MSP (mMSP) of 30 μm diameter would
be best suited for drug delivery (7). This technique also
seems promising in the treatment of AKI, since mMSP
can be injected subcapsularly, leading to local release
directly into the kidney. We propose to deliver existing
drugs against kidney disease, since these drugs are often
difficult to dose, requiring frequent blood monitoring
and dose adjustments (8) to reduce or prevent adverse
effects. A more gradual release of drug released locally
from mMSP may prevent high blood levels and thus
prevent side-effects.
Rapamycin has been shown to reduce inflammation in
kidney injury models (9,10). Based on these findings we now
hypothesized that subcapsular delivery of rapamycin, using
mMSP can modulate the renal microenvironment in an
AKI model (ischemia/reperfusion injury, IRI) in rats.
MATERIALS AND METHODS
Preparation of Placebo and Rapamycin-Loaded
Monospheres
MSP were prepared using SynBiosys 20[PDLA-PEG1000]-
80[PLLA], a multiblock copolymer consisting of 20% w/w of
poly(DL-lactide)-PEG1000-poly(DL-lactide) with a molecular
weight of 2000 g/mol and 80% w/w of poly(L-lactide) with a
molecular weight of 4000 g/mol (InnoCore Pharmaceuticals,
Groningen, The Netherlands).
Monodisperse MSP (monospheres, mMSP) were prepared
by a membrane emulsification-based solvent extraction/
evaporation process using an Iris-20 microsieve membrane
with uniformly sized pores of 20 μm (Nanomi BV,
Oldenzaal, The Netherlands).
For placebo (drug-free) mMSP approximately 3.0 g of
20[PDLA-PEG1500]-80[PLLA] polymer was dissolved in
9 mL dichloromethane (DCM, p.a. stabilized with EtOH,
Across, Geel, Belgium) as to obtain a 20% w/w solution and
filtered through a 0.2 mm PTFE filter. The filtered
polymer solution was processed through the microsieve
membrane using 35 mbar air-pressure into an aqueous
solution containing 4% w/v polyvinylalcohol (PVA 13–
23, Sigma-Aldrich, Zwijndrecht, the Netherlands) as
emulsifier thereby forming a dispersion of mMSP. This
dispersion was stirred for at least 3 h at room temper-
ature to extract and evaporate the solvent. The hardened
MSP were concentrated by filtration and washed repeatedly
with ultrapure water containing 0.05% Tween20 (Across) and
finally lyophilized.
For rapamycin-loaded MSP, rapamycin (Sirolimus, LC
Laboratories, Woburn, USA) was co-dissolved with the
20[PDLA-PEG1500]-80[PLLA] polymer to obtain a solution
containing 20% w/w 20[PDLA-PEG1500]-80[PLLA] and
5% w/w rapamycin, which was used to prepare MSP using
the same procedures as described above. Placebo mMSP and
rapamycin-loaded mMSP were stored at −20°C until
evaluation.
Rapamycin Content of Monospheres
Rapamycin loading was determined by immersing
mMSP (5–10 mg) in 600 μL of acetone:ethanol (2:1v/v) to
extract rapamycin. After 1 h, the mMSP were centrifuged at
10,000g for 20 min, whereafter the rapamycin concentration
of the supernatant was determined by HPLC. HPLC was
performed on a Waters 2695 Alliance system (Etten-Leur,
The Netherlands) consisting of a 2998 Photodiode array
detector and a computer with Empower 2 Software.
Prior to analysis, the samples were filtered over an
0.2 μm PTFE filter. Separation was perfomed using
anXterra RP18 (4.6×150mm, 3.5 μm) reverse phase column
(Waters, Etten-Leur, The Netherlands) at 50°C using a flow
rate of 1.0 mL/min and an injection volume of 20 μL. The
mobile phase was acetonitrile:water (70:30v/v). Rapamycin
was detected by UV absorption at a wavelength of 278 nm.
The standard curve of rapamycin was established and the
concentration of unknown samples was calculated from the
standard curve. The linearity was 0.999 in the range of
0.5 μg/g to 500 μg/g. Rapamycin MSP contained
18.4% w/w of rapamycin, representing an encapsulation
efficiency of 99.1%.
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Animals and mMSP Administration Procedures
Male, 9 to 11 weeks old F344 rats (Harlan Laboratories, Inc.
Livermore, USA), weighing 240±50 g, underwent unilateral
left kidney ischemia reperfusion injury (IRI) by clamping the
renal artery and vein for 45 min. Prior to clamping, two sub-
capsular pockets were generated on the left kidney, in which
either placebo mMSP, low-dose rapamycin-mMSP
(0.37 mg rapamycin, obtained by mixing rapamycin
MSP with placebo MSP 1:5), or high-dose rapamycin-
mMSP (1.84 mg rapamycin) were injected (5 mg MSP/
pocket). Alternatively, placebo-MSP or high-dose
rapamycin-MSP were injected subcutaneously on the
back of rats with unilateral IRI, to achieve systemic
drug delivery. All rats were sacrificed after 7 or 14 days
(N=7/group for subcapsular implantations and N=5/
group for subcutaneous implantations). Kidneys were
flushed with saline and fixed in Zinc fixative (0.1 M
Tris-buffer, 3.2 mM calcium acetate, 23 mM Zinc ace-
tate, 37 mM zinc chloride, pH 6.5–7.0; Merck) over-
night, prior to paraffin embedding. Kidney samples
were cut into 4.0 μm-thick sections. Blood samples were
collected from each rat on day 0, 3, 7, 10 and 14 by orbital
puncture and collected in EDTA tubes. Rapamycin amounts
in the blood were determined by LC-MS/MSmass spectrom-
etry using a previously describedmethod (11) and [13C,2H3]-
Sirolimus (SAS Alsachim, Illkirch, France) as an internal stan-
dard performed by the Mass Spectometry Core Facility
(UMCG Groningen, The Netherlands). Plasma creatinine
levels were determined according to standard procedures
(Clinical laboratory UMCG Groningen, The Netherlands).
(Immuno)histochemistry
Paraffin sections were dewaxed in xylene and rehydrated in
ethanol. Characteristics of the primary antibodies used are
summarized in Table I. Heat-induced antigen retrieval was
performed using a 0.1 M Tris–HCl buffer, pH 9 (α-SMA,
ED1) or 10 mM citrate buffer, pH 6.0 (LC-3). Enzymatic an-
tigen retrieval was performed using protease K (collagens type I
and III). Washing and blocking of aspecific binding sites, en-
dogenous peroxidases and endogenous biotin was performed
according to standard procedures. Stainings for ED1, α-SMA
and LC-3 were visualized using 3-Amino-9-ethylcarbazole
(AEC; Sigma-Aldrich, Zwijndrecht, Netherlands), stainings
for collagens I and III were visualized using a Vector Red kit
according to the manufacturer’s instructions (Vector
Laboratories, Burlingame, CA). All tissue sections were coun-
terstained with hematoxylin (Merck, Darmstadt, Germany)
and mounted in Kaiser’s glycerin-gelatin (Merck).
General histological assessment of the tissue reaction to-
wards the mMSP was based on a periodic acid-Schiff staining,
according to a standard staining protocol (Department of
Pathology, University Medical Centre Groningen,
Groningen, The Netherlands). Tissue sections were mounted
in permount (Fisher Scientific International).
Quantification of Stainings
Stainings were evaluated using a Leica DM 2000 microscope.
For morphometric quantifications, five representative photo-
micrographs at 20× magnification were taken per section,
using a Multispectral Imaging Camera (Perkin Elmer,
Cambridge, UK). All photomicrographs were taken directly
underneath the site of implantation of the microspheres, or at
an equivalent site in the kidneys of rats that had received a
subcutaneous implant. The photomicrographs were analysed
using Nuance 3.0 software (Perkin Elmer). Stained areas were
quantified and expressed as average surface area in square
micrometer per high power field (μm2/HPF).
Statistics
Statistical differences between groups were determined using
a Kruskal–Wallis test, followed by a Dunn’s Multiple
Comparison test to examine differences between each placebo
and rapamycin combination separately. GraphPad Prism ver-
sion 5 (GraphPad Software, La Jolla, USA) was used for all
calculations. P values<0.05 were considered to be statistically




The measurement of rapamycin concentrations in the circu-
lation provides insight into the in vivo release of rapamycin
Table I Antibodies Used in this Study
Manufacturer Dilution
Primary antibody
Mouse-anti-rat ED1 AbD Serotec 10 μg/ml
Mouse anti-α-SMA Clone 1A4, DAKO 0.44 μg/ml
Mouse anti-collagen I Abcam 1 μg/ml
Mouse anti-collagen III Abcam 0.64 μg/ml
Rabbit anti-LC3 Novus Biologicals 20 μg/ml
Secondary antibody
Rabbit-anti-mouse-HRP DAKO 13 μg/ml
Rabbit-anti-mouse HRP DAKO 13 μg/ml
Goat-anti-mouse-biotin DAKO 5 μg/ml
Goat-anti-mouse-biotin DAKO 5 μg/ml
Goat-anti-rabbit-biotin DAKO 8.2 μg/ml
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from the mMSP. Release of rapamycin into the circulation
was detected in all three rat groups treated with rapamycin-
containing mMSP and showed a dose dependency, as seen
when comparing the subcapsular low dose (RCL) with the
high dose (RCH). The highest blood levels of rapamycin were
2.5–3 nM, which were observed on day 3, and decreased
subsequently in time. Release of rapamycin was sustained
for at least 14 days. Interestingly, in rats implanted with the
high dose rapamycin mMSP either subcutaneously or
subcapsularly, there was no difference in blood rapamycin
levels (Fig. 1). Since our effect studies did not show significant
differences between RCL and RCH groups, or control and
RCL groups (Suppl. Fig. 1), the remainder of the paper will
focus on the effects of subcapsular and subcutaneous delivery
of high dose rapamycin, hereafter defined as local and system-
ic delivery respectively.
Effect of Subcapsular Injection of mMSP on Kidney
Morphology and Function
To determine the effects of injecting mMSP underneath the
kidney capsule on kidney morphology we performed a PAS
staining (Fig. 2a). The PAS staining showed a slightly thick-
ened kidney capsule, which may be caused by the technique
used to create subcapsular pockets. However, more impor-
tantly, the injection of mMSP itself did not alter kidney cortex
morphology in any way, compared to rats that had also un-
dergone ischemia-reperfusion but were not injected with
mMSP subcapsularly.
In addition, mMSP subcapsular injections did not have a
negative effect on kidney function, as revealed by plasma cre-
atinine levels (Fig. 2b). These findings are very important because if local drug delivery in the kidney is to be a feasible
future treatment, the injectionmethod itself should not disturb
kidney function or morphology.
Macrophage Infiltration and Presence/Formation
of Myofibroblasts
The inflammatory response after ischemia reperfusion injury
(IRI) is predominantly an innate immune response which is
characterized by polymorphonuclear (PMN) cell infiltration in
the early phase, followed by macrophage infiltration later in
IRI (12).We focused onmacrophage infiltration, a key marker
of the later inflammatory response. Local release of rapamycin
by mMSP led to a lower macrophage influx compared to
placebo mMSP (Fig. 3a), measured as ED-1 staining. No de-
crease of ED-1 was observed after systemic delivery of
rapamycin via subcutaneous administration of rapamycin
mMSP. The same trend was observed on day 14 (Suppl.
Fig. 2A), when local delivery of rapamycin also decreased
macrophage influx while systemic delivery did not.
Fig. 1 Blood levels of rapamycin. Blood rapamycin concentrations were
determined in whole blood by HPLC mass spectrometry. Bars represent
mean values and SEM. Scale bar represent 100 μm. Abbreviations: PSc place-
bo subcutaneous, RSc rapamycin subcutaneous high dose, PC placebo sub-
capsular, RCL rapamycin low dose, RCH rapamycin subcapsular high dose.
Fig. 2 Effect of subcapsular injection of (Rapamycin) mMSP on kidney func-
tion. Placebo mMSP and rapamycin mMSP were injected subcapsularly in a
model of IRI and explanted on day 7. Placebo mMSP are visible as white
spheres localized between kidney capsule and kidney cortex (a). Kidney func-
tion was determined based on plasma creatinin levels (b). Abbreviations: PSc
placebo subcutaneous, RSc rapamycin subcutaneous high dose, PC placebo
subcapsular, RCH rapamycin subcapsular high dose.
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Myofibroblast Accumulation
Upon damage, fibroblasts can be activated into myofibroblasts,
which deposit collagens as a way of strengthening the damaged
tissue. In normal wound-healing these cells undergo ap-
optosis after healing is complete. Although rats recover
quickly from IRI damage, without long term collagen
accumulation, the presence of myofibroblasts in the
short term is still an important marker for tissue dam-
age. Therefore we performed an immunostaining
(Fig. 4a) for myofibroblasts (α-SMA) and found a signif-
icant decrease in α-SMA positivity when rapamycin was
administered locally, but not when it was administered
systemically (Fig. 4b). This significant difference was no
longer present on day 14 (Suppl. Fig. 2B).
Proliferation
It is known that rapamycin has anti-proliferative effects (13),
therefore we examined whether a decrease in proliferation
could explain the decrease seen in both ED-1 and α-SMA
expression (see above) after local rapamycin treatment. We
found no differences in Ki-67 positive cells between placebo
and rapamycin treated rats (data not shown).
Fig. 3 Renal interstitial macrophage infiltration after subcutaneous and subcapsular delivery of rapamycin or placebo. Placebo mMSP and rapamycin containing
mMSP were injected subcutaneously and subcapsularly in a model of IRI and explanted at day 7. ED-1 staining was performed to assess renal interstitial
macrophage infiltration (a). Average macrophage area was determined by morphometry (b). Scale bars represent 100 μm. Bars represents mean values and
SEM. * P<0.05, HPF high power field.
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Collagen Deposition
In response to ischemic injury, extracellular matrix is deposit-
ed in the kidney interstitium by myofibroblasts. We character-
ized the effects of local and systemic treatment with rapamycin
on the deposition of two main types of collagen, i.e., collagen I
and III, by immunostaining. Deposition of collagen type I on
day 7 was significantly higher after local treatment with
rapamycin compared to placebo-MSP, while no significant
effect of systemic rapamycin treatment was seen (Fig. 5a).
On day 14 the difference between placebo and rapamycin-
loaded MSP local treatment was still visible (Suppl.
Fig. 2C). No significant differences were found in the
deposition of collagen type III at any time point after local
or systemic delivery (Fig. 5b and Suppl. Fig. 2D).
Autophagy
Rapamycin has been described to directly induce autophagy,
which has also been reported to be a factor in the recovery
after AKI. We assessed protein levels of LC-3, a component of
the autophagosome, in kidney sections of rats treated system-
ically and locally with rapamycin (Fig. 6a). Levels of LC-3
were slightly increased after systemic delivery of rapamycin.
However, this increase was only significant after local
rapamycin delivery (Fig. 6b), indicating an increased
Fig. 4 Renal interstitial myofibroblast accumulation after subcutaneous and subcapsular delivery of rapamycin or placebo. PlaceboMSPand rapamycinMSP were
injected subcutaneously and subcapsularly in a model of IRI and explanted at day 7. αSMA staining was performed to detect renal interstitial myofibroblasts (a).
Average myofibroblast area was determined by morphometry (b). Scale bars represent 100 μm. Bars represents mean values and SEM. HPF high power field.
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rapamycin-related drug effect in kidneys treated locally with
rapamycin on day 7.On day 14 no significant differences were
present anymore (Suppl. Fig. 2E).
DISCUSSION
This study shows that rapamycin can be delivered
subcapsularly by means of sustained release mMSP over a pe-
riod of 2 weeks. The mMSP successfully released rapamycin in
a time-dependent manner into the circulation and into the
kidney. Both the subcutaneous as well as the subcapsular ad-
ministration route resulted in very low systemic levels of
rapamycin, with similar in vivo release patterns, suggesting that
drug release from these mMSP is not altered by the injection
site. Furthermore, the effects seen in the kidney were not due to
prolonged exposure to low systemic drug levels, but specifically
caused by the local depot, since the subcutaneous delivery route
did not result in major alterations in kidney recovery after IRI.
Injection at either site led to systemic rapamycin concentrations
below therapeutic levels, which are approximately 5–8 ng/ml
in humans (8) and approximately 10 ng/ml in rats (14). Using
identical doses of rapamycin, effects in the kidney were signif-
icantly more pronounced when the drug was delivered
subcapsularly, than when it was delivered subcutaneously.
Notably, we still found detectable levels of rapamycin in
blood 14 days after implantation of mMSP, although previous
in vitro studies using similar mMSP indicated that all rapamycin
would be released within 7 days (15). Since the reported half-
life of rapamycin in rats is approximately 31 h (16), the sustained
blood levels are unlikely to be caused by circulating rapamycin.
Therefore, other factors related to the release of rapamycin in vivo
may be responsible for the presence of rapamycin up to at least
14 days after implantation of the mMSP. Falke et al. (15) also
reported in vivo plasma levels of rapamycin 7 days after subcap-
sular implantation of mMSP to be below 2 μg/L. At this time-
point, using a different method, we found a rapamycin concen-
tration in blood of 1.5–2 nM (corresponding to 1.4–1.8 μg/L)
which shows the levels in our study to be in accordance with
previously published results.
A recent study also showed beneficial effects of subcapsular
delivery of rapamycin in a unilateral ureteral obstruction
model (15), which causes renal fibrosis. This study also found
a significant decrease in side-effects after subcapsular admin-
istration, since they found a loss of bodyweight only in their
control group, where we found no systemic side effects con-
nected to either the rapamycin subcutaneous or subcapsular
treatment. However, in the previous study subcapsular deliv-
ery was compared to daily i.p. injections of rapamycin, where-
as our study used subcutaneous depots as a control, ensuring
Fig. 5 Renal deposition of collagen I and III after subcutaneous and subcapsular delivery of rapamycin or placebo. PlaceboMSPand rapamycin MSPwere injected
subcutaneously and subcapsularly in a model of IRI and explanted at day 7. Collagen I (a), III (b) stainings were performed in order to assess renal interstitial
extracellular matrix deposition. Average Collagen I and III area were determined by morphometry (c and d respectively). Scale bars represent 100 μm. Bars
represents mean values and SEM. * P<0.05, HPF high power field.
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comparison of continuous delivery and avoiding peaks in
blood rapamycin levels.
The method itself, consisting of the injection of mMSP
underneath the kidney capsule (between capsule and cortex)
has been refined compared to current subcapsular injections
(17) and did not induce cortical damage at the site of implan-
tation, or affect kidney function. Notably, in contrast to this
earlier study, we performed implantation of mMSP in kidneys
which also underwent IRI, showing that the procedure is safe
in damaged kidneys as well.
Our results show that local subcapsular drug delivery of
rapamycin in a model of IRI results in reduced macrophage
and myofibroblast numbers. The question arises whether
this decrease is due to reduced infiltration or reduced
proliferation of macrophages. Although rapamycin has
anti-proliferative effects (13), Ki-67 staining within our
experimental groups revealed no differences in cell pro-
liferation in the kidney between any of the experimental
groups. This suggests that local rapamycin delivery di-
rectly decreases macrophage influx or recruitment into
the kidney, rather than inhibiting local proliferation.
The decrease in myofibroblasts may be a secondary ef-
fect to the decrease in macrophages. It has been demon-
strated that macrophages can produce highly fibrogenic
Fig. 6 Renal expression of autophagy marker LC3 after subcutaneous and subcapsular delivery of rapamycin or placebo. PlaceboMSP and rapamycin containing
MSP were injected subcutaneously and subcapsularly in a model of IRI and explanted at day 7. LC3 staining was performed in order to detect autophagy induction
as a marker for rapamycin release (a). Average LC3 area was determined by morphometry (b). Scale bars represent 100 μm. Bars represents mean values and
SEM. * P<0.05 HPF high power field.
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growth factors such as transforming growth factor-β and
platelet derived growth factor (18). A decrease in the
amount of macrophages could thus lead to a decrease
in the cytokines that induce activation of fibroblasts into
myofibroblasts.
We hypothesized that an early intervention in the acute
phase of the kidney injury would provide us with a valuable
tool to inhibit the progression towards kidney fibrosis. In this
study we succeeded in decreasing the inflammatory response,
and we successfully reduced the amount of myofibroblasts in
the kidney, which are considered to be the main collagen
producing cells (19–21). However, this therapeutic effect did
not result in decreased interstitial collagen deposition, but in
an increase in collagen type I. A previous study reported that
rapamycin may delay recovery after IRI (22), showing that
normalization of GFR and proliferation of tubular epithelium
occurred at a later time-point, but this study did not address
collagen deposition. Possibly in the present study the delay in
recovery is reflected in higher collagen levels in rapamycin-
treated kidneys compared to those treated with placebo. In
this respect, it may be notable that all rapamycin-treated
groups showed a slight increase in blood creatinin levels,
although this increase was only significant in rats im-
planted with mMSP subcutaneously, which did not
show a significant increase in collagen. Macrophage
and myofibroblast presence were determined based on
expression of ED-1 and α-SMA respectively. These cell-
type markers are conceivably more transient than colla-
gen, once it is deposited. The discrepancy between high
collagen levels and decreased α-SMA positive myofibroblasts
may therefore also be explained if α-SMA myofibroblasts
have decreased already, while collagen has not been cleared
yet. Since matrix metalloproteinases (MMPs) are normally
mostly produced by macrophages (23,24), and macrophages
were also decreased by rapamycin treatment in our study, it is
possible that the deposited collagen was not cleared due to a
lack of MMPs. However, an increased deposition of collagen
by other cell types than myofibroblasts cannot be excluded
based on our findings.
Rapamycin has previously been shown to directly in-
duce autophagy in a variety of cell types in the kidney
(25). Autophagy is known as a cell survival process dur-
ing starvation. However, whether this process is benefi-
cial in the IRI model is currently under debate (26–28).
We used LC-3, a component of autophagosomes, as a
marker for the induction of autophagy. We indeed ob-
served a dramatic increase in autophagy in rats treated
locally with rapamycin compared to systemic delivery.
The increase in autophagy, regardless of its role in
AKI, gives additional evidence for strong local inhibi-
tion of mTOR signaling after subcapsular delivery of
rapamycin, suggesting higher local levels of rapamycin
than those which were achieved after systemic delivery.
CONCLUSION
The main goal of this study was to investigate whether local
delivery of rapamycin using subcapsular injection of mMSP
would be superior compared to systemic delivery. Based on
our results we conclude that subcapsular implantation of
mMSP itself does not induce adverse effects. Furthermore,
rapamycin was effectively released from the mMSP and in-
creased drug effects were seen after local delivery compared to
systemic delivery from a subcutaneous mMSP depot. Thus
injection of drug-containing monospheres underneath the re-
nal capsule is a safe and useful method to increase drug
effectivity.
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